Zydus Lifesciences Limited
https://www.zyduslife.com/index
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Zydus Lifesciences Limited
Deal Watch: Shionogi Will Market Nxera’s Insomnia Drug In Japan
Plus deals involving Jiangsu Alphamab/CSPC, Zydus/CDRI, Junshi/JSIAMA, Repair/Genevant, Sanofi/I-Mab, Novartis/Mitem and BioAtla/Context.
Sandoz Among Defeated As US Federal Circuit Breathes New Life Into US Myrbetriq Patent
A US district court “misapprehended its role in adjudicating the issue of patentability,” the US Federal Circuit found, as it vacated and remanded the lower court’s US patent invalidity decision, raising fresh questions in a market that has already seen generic launches from a pair of manufacturers.
Zydus Signs MRI Contrast Agent Licensing Deal With A Market Worth Of $237m
Zydus bags two generic gadolinium-based contrasting agents in an exclusive licensing and supply agreement with Viwit, opening a new chapter of imaging injectables for the US market.
US Generics Players Enjoy Calmer Waters
After years of heavy price and cost pressures that have taken a toll on firms operating in the US generics market, more recent quarters appear to have reflected a calmer and more predictable landscape.
Company Information
- Industry
-
Pharmaceuticals
- Generic Drugs
- OTC, Consumer
- Other Names / Subsidiaries
-
- Cadila Healthcare
- Zydus Pharmaceuticals USA
- German Remedies
- Zynesher Pharmaceuticals USA LLC
- Nesher Pharmaceuticals Inc
- Quimica e Farmaceutica Nikkho do Brasil Ltda
- Bremer Pharma GmbH
- Nippon Universal Pharmaceuticals
- Zydus Discovery DMCC
- Zydus Urosciences
- Sentynl Therapeutics, Inc
- Zydus Lifesciences Ltd
- Cadila Healthcare Ltd.
- Zydus Cadila
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice